Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.

People with stage IV melanoma treated with anti-PD-1 therapy had serial tumor-informed ctDNA testing, and a landmark analysis at 6 and 9 months was used to assess progression. The abstract does not name the manufacturer.

CancersPubMed 41375005DOI 10.3390/cancers17233804